Inventiva S.A. INDEX TO UNAUDITED INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS Page Unaudited Interim Condensed Consolidated Financial Statements as of

TO UNAUDITED INTERIM CONDENSED CONSOLIDATED FINANCIAL

Unaudited interim condensed consolidated

statement of financial position

(in thousands of euros)

The accompanying notes form an integral part of these financial

Unaudited interim condensed consolidated

statement of income (loss)

(in thousands of euros, except share and per share amounts)

The accompanying notes form an integral part of these financial

Unaudited interim condensed consolidated statement of comprehensive

(in thousands of euros)

The accompanying notes form an integral part of these financial

Unaudited interim condensed consolidated statement of cash flows

(in thousands of euros)

The accompanying notes form an integral part of these financial

Unaudited interim condensed consolidated statement of changes

in shareholders' equity

(in thousands of euros, except share amounts)

Notes to the unaudited interim condensed consolidated financial

Inventiva is a public limited company registered

and domiciled in France. Its head office is located at 50 rue de Dijon, 21121 Daix. The consolidated nancial statements of the

company Inventiva include Inventiva S.A. and its subsidiary Inventiva Inc., created in January 2021 (the group designated as "Inventiva"

Inventiva is a clinical-stage biopharmaceutical

company focused on the development of oral small molecule therapies for the treatment of non-alcoholic steatohepatitis, or NASH, mucopolysaccharidoses,

or MPS, and other diseases with significant unmet medical need.

Leveraging its expertise and experience in the

domain of compounds targeting nuclear receptors, transcription factors and epigenetic modulation, Inventiva is currently advancing two

clinical candidates, as well as a deep pipeline of earlier stage programs:

Inventiva's ordinary shares have been listed

on compartment C of the Euronext Paris regulated market since February 2017 and Inventiva's American Depositary Shares (ADSs), each

representing one ordinary share, have been listed on the Nasdaq Global Market since July 2020.

On January 5, 2021, Inventiva announced

design of Phase III clinical trial with lanifibranor in NASH - planned for the first half of 2021 - seeks to obtain accelerated

approval in the U.S. and conditional approval in the European Union

See note 1.1 Company information

Collaboration in the field of NASH biomarkers

with Professor J r me Boursier, M.D., Ph.D

On February 25, 2021, the Company announced its

collaboration in the field of NASH biomarkers with Professor J r me Boursier, M.D., Ph.D, Professor of Medicine at the Faculty

of Medicine of Angers University. The objective of the collaboration is to develop one or several biomarkers or a composite biomarker

score to identify patients responding to lanifibranor with regards to NASH resolution and fibrosis improvement.

Guarantee given to the tax authorities

On January 6, 2021, following the favorable response

of the tax authorities to the request for a stay of payment of the payroll tax for fiscal years 2016 and 2017, the Company carried out

a guarantee, in the form of a bank guarantee from Cr dit Agricole, in the amount of 1.0 million (see Notes 12 "Provisions"

and 14.2 "Other current liabilities").

Tax audit for payroll taxes for fiscal years

On January 25, 2021 the Administrative Court of

Dijon informed the Company of the dismissal of the contentious claim regarding the amounts claimed for the fiscal years 2013, 2014 and

2015. Abbott led the defense strategy under the existing agreements and decided not to conduct the appeal procedure with the Administrative

Court of Lyon (Tribunal Administratif de Lyon). Furthermore, the Company decided not to conduct the appeal process itself.

On February 10, 2021 the Company requested the

payment from Abbott of the 2.0 million corresponding to the maximum amount covered by the indemnity under the Additional Agreement.

The entire payment was received during the first quarter of 2021 (see Note 8.2 "Other current assets and receivables").

On February 11, 2021, the Company received formal

notice to pay the amounts due to the French tax authorities under the AMR issued on August 17, 2018 for an amount of 1.9 million.

As of the date of issuance of these unaudited interim condensed consolidated financial statements, in accordance with the French tax authorities,

the Company paid 1.8 million euros, corresponding to the amounts due and late payment interest, including 1.3 million euros by offsetting

VAT credit receivables (refer to Notes 12. "Provisions", 14.2 "Other current liabilities" and 24. "Events

after the reporting date").

Creation of Inventiva U.S. subsidiary, Inventiva Inc.

Inventiva Inc. was incorporated in the state of

New Jersey on January 5, 2021. Inventiva owns 100% of the stock of its U.S. affiliate. Inventiva Inc. will act as service provider for

its parent company in the United States, including in connection with the Phase III clinical trial for lanifibranor, which is planned

for the first half of 2021. The affiliate started its operations at the end of the first quarter of 2021 with the recruitment of its first

employees and in particular the Chief Medical Officer ("CMO"), employee of Inventiva Inc. since April 2021.

As of March 31, 2021, the Company's financial

statements were supplemented for the first time, by consolidation of the 100% held U.S. subsidiary.

Impact of the COVID-19 pandemic

date of issuance of these unaudited interim condensed consolidated financial statements,

the COVID-19 pandemic did not impact significantly the Company's business activities, financial position and operating results.

of issuance of these unaudited interim condensed consolidated financial statements, the Company

was not aware of any specific events or circumstances that would require it to update its estimates, assumptions and judgments or to revise

the carrying amounts of its assets and liabilities. Such estimates may be adjusted as new events occur and additional information

is obtained. The adjustments will be recognized in the interim financial statements as soon as the Company becomes aware of the new events

or the additional information. Actual results may differ from the estimates and any differences may be material for the financial statements.

Following the creation of the subsidiary Inventiva

Inc. in January 2021 (see note 1.2 "Significant events during the first quarter of 2021"), the Company prepares for the first

time the consolidated financial statements for its quarterly closing as of March 31, 2021.

The Company has prepared these unaudited interim

condensed consolidated financial statements in accordance with International Financial Reporting Standards ("IFRS") as adopted

by the European Union and IFRS as issued by the International Accounting Standard Board ("IASB").

These unaudited interim condensed consolidated

financial statements as of March 31, 2021 and for the three months ended March 31, 2021 were approved by the Board of Directors of

the Company on June 22, 2021.

These unaudited interim condensed consolidated

financial statements were prepared in compliance with International Accounting Standards (IAS) 34-Interim Financial Reporting,

which provides for the presentation of selected explanatory notes. The accompanying notes do not contain all the disclosures required

for annual financial statements and should therefore be read in conjunction with the Company's financial statements prepared in

accordance with IFRS as of and for the year ended December 31, 2020.

For more details on the scope and the basis of

consolidation, refer to Note 2.3 "Basis of consolidation" below.

The accounting policies applied by the Company